Bromodomain and extra-terminal (BET) protein inhibitors have been reported as treatment options for acute myeloid leukemia (AML) in preclinical models and are currently being evaluated in clinical tri
Poly(ADP-ribose) polymerase 1 (PARP-1) is abnormally expressed in a wide variety of tumors. Emerging evidence suggests that PARP-1 plays key roles in multiple biologic behaviors of tumors, such as mod
N6-methyladenosine modification (m6A) fine-tunes RNA fate in a variety of ways, thus regulating multiple fundamental biological processes. m6A writers bind to chromatin and interact with RNA polymeras
